TB R&D Weekly Update: Totally Drug-Resistant TB

Over the past couple of weeks there have been much discussion and reporting on totally drug-resistant tuberculosis (TDR-TB) based on reports of new cases in India. Here are links to coverage of TDR-TB in India, excerpt from a response by Dr. Nardell who we interviewed last year, and link to the WHO Fact Sheet on TDR-TB.


Totally drug-resistant TB emerges in India (Nature)

Totally Resistant TB: Earliest Cases in Italy (Wired)

TB That Resists All Drugs Is Found In India (NPR)

Totally drug-resistant TB at large in India (New Scientist)

No city lab can certify TDR-TB (The Times of India)

Excerpt from e-mail from Dr. Edward Nardell on January 12, 2012 to the CORE Group–TB in response to the article on

“While the emergence and spread of highly drug resistant strains has been a long-standing concern, strains resistant to all drugs is not new, and has been a by-product of introducing treatment for MDR TB long before XDR TB. Having been engaged early on in the treatment of MDR TB in Peru, Haiti, and Russia, PIH has encountered highly drug resistant strains, now called XDR and TDR, long before there were any headlines about them. Others have seen the same. Such cases were simply called MDR treatment failures and became chronic cases. As MDR treatment has spread, their numbers have increased. No treatment = no resistance, but that is hardly a solution. Well supervised treatment results in less resistance, of course, but even well supervised treatment can induce some resistance and it can spread in families and congregate settings. Like XDR, TDR will generate headlines and may generate some beneficial resources, but there is nothing new in principle here. Certainly we have a problem with DST’s for second-line drugs. Two good labs may not agree on resistance patterns which make the reporting of MDR, XDR, and TDR always questionable, but again, in principle, the emergence of such strains, when confirmed, is not surprising or new.”

Edward A. Nardell, MD, Associate Professor, Harvard Medical School (Medicine; Global Health and Social Medicine), Harvard School of Public Health (Environmental Health; Immunology and Infectious Diseases)

WHO Fact Sheet on Totally Drug Resistant TB

Additional TB R&D News:

QIAGEN and Max Planck Institute for Infection Biology Collaborate to Develop Assay for Active TB Risk in Individuals With Latent Infection

Antimycobacterials from natural sources: ancient times, antibiotic era and novel scaffolds

Re-evaluation of the critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against pyrazinamide using wild-type MIC distributions and pncA gene sequencing

Inhibition of Bacterial Carbonic Anhydrases and Zinc Proteases: From OrphanTargets to Innovative New Antibiotic Drugs

More News
23 Aug 2022
Last week, the PAN-TB collaboration announced initial plans for a Phase 2 clinical trial evaluating two novel drug regimens to treat Tuberculosis. Sponsored by the Bill and Melinda Gates Foundation, the PAN-TB, or “Project to Accelerate New Treatments for Tuberculosis”, collaboration brings...
4 May 2022
Earlier this week, the World Health Organization (WHO) released a rapid communication which detailed the upcoming changes to the treatment guidance for drug-resistant tuberculosis (DR-TB). These guidelines are used to inform national TB programmes globally on how to treat patients with these...
5 Apr 2022
On April 01, 2022, the Stop TB Partnership launched the second online consultation for the new Global Plan to End TB 2023-2030. Over the years, the Global Plans have been important tools for advocacy and resource mobilization, and served as a reference document for donors and stakeholders. In May...